Results 41 to 50 of about 36,737 (275)

Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome [PDF]

, 2013
Background Cardiac amyloidosis is a fatal disease whose prognosis and treatment rely on identification of the amyloid type. In our aging population transthyretin amyloidosis (ATTRwt) is common and must be differentiated from other amyloid types.
Banypersad, SM, Dungu, J, Gibbs, SD, Gilbertson, JA, Gillmore, JD, Hawkins, PN, Lachmann, HJ, McCarthy, CA, Petrie, A, Pinney, JH, Rowczenio, D, Sattianayagam, P, Venner, CP, Wassef, N, Wechalekar, A, Whelan, CJ   +15 more
core   +1 more source

Duodenal biopsy: an unexpected confirmatory test for a patient with al-amyloidosis

Sri Lanka Journal of Medicine, 2019
SSystemic AL- amyloidosis is a disorder of protein folding in which there is extra-cellular accumulation as β pleated fibrillar deposits of monoclonal immunoglobulin light chain fragments. AL- amyloidosis is a rare clinical entity.
S. Pirasath, T. Kumanan, G. Selvaratnam, V. Sujanitha, D. D. Dikowita   +4 more
doaj   +1 more source

Syndrome in Question [PDF]

Anais Brasileiros de Dermatologia, 2015
Immunoglobulin light chain amyloidosis is the most common acquired systemic amyloidosis. Its presentation is often insidious and progressive, which may delay diagnosis.
Han MA, Meilan Chen, Juan Li, Ying Li, Shu Qiu   +4 more
doaj   +1 more source

Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis

Hemato, 2021
Non-native immunoglobulin light chain conformations, including aggregates, appear to cause light chain amyloidosis pathology. Despite significant progress in pharmacological eradication of the neoplastic plasma cells that secrete these light chains, in ...
Gareth J. Morgan, Joel N. Buxbaum, Jeffery W. Kelly   +2 more
doaj   +1 more source

Natural history and outcome in systemic AA amyloidosis [PDF]

, 2007
BACKGROUND:Deposition of amyloid fibrils derived from circulating acute-phase reactant serum amyloid A protein (SAA) causes systemic AA amyloidosis, a serious complication of many chronic inflammatory disorders.
Gallimore, JR, Gilbertson, JA, Gillmore, JD, Goodman, HJB, Hawkins, PN, Lachmann, HJ, Sabin, CA   +6 more
core   +1 more source

Amyloidosis: a case series and review of the literature

Journal of Medical Case Reports, 2023
Background Systemic amyloidosis is group of disorders characterized by the accumulation of insoluble proteins in tissues. The most common form of systemic amyloidosis is light chain amyloidosis, which results from the accumulation of misfolded ...
Justin B. Senecal, Romel Abou-Akl, Pat Allevato, Ian Mazzetti, Caroline Hamm, Richa Parikh, Indryas Woldie   +6 more
doaj   +1 more source

Pseudoxanthoma Elasticum and Light-Chain Amyloidosis [PDF]

European Journal of Inflammation, 2012
Pseudoxanthoma elasticum is a heritable disorder of connective tissue characterized by cutaneous, vascular and ocular changes that result from the accumulation of fragmented elastic fibres. Even though the etiopathogenesis is not still completely understood, in recent years in literature some Authors have considered pseudoxanthoma elasticum as a ...
M. Carlesimo, C. Abruzzese, G. Cortesi, A.M. Ciccone, C. Poggi, M. Lombardi, A. Moscetti, G. La Verde, E. Mari   +8 more
openaire   +2 more sources

Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis [PDF]

, 2013
Background: We compared a novel assay for free light chain (FLC) quantitation based on monoclonal antibodies (N-Latex, Siemens, Germany) to the established polyclonal antibody-based assay (Freelite (TM), The Binding Site, UK) in AL ...
Campbell, Campbell, Comenzo, Comenzo, Davern, Davern, Dispenzieri, Dispenzieri, Katzmann, Katzmann, Kumar, Kumar, Kumar, Kumar, Lachmann, Lachmann, Mollee, Mollee, Morris, Morris, Palladini, Palladini, Palladini, Palladini, Palladini, Palladini, Pretorius, Pretorius, Tate, Tate, Tate, Tate, Velthuis, Velthuis   +33 more
core   +1 more source

Biomarkers in Immunoglobulin Light Chain Amyloidosis

Klinicka Onkologie, 2017
Immunoglobulin light chain amyloidosis (AL amyloidosis - ALA) is a monoclonal gammopathy characterized by presence of aberrant plasma cells producing amyloidogenic immunoglobulin light chains. This leads to formation of amyloid fibrils in various organs and tissues, mainly in heart and kidney, and causes their dysfunction.
Kufova, Z., Sevcikova, T., Growkova, K., Vojta, P., Filipova, J., Adam, Z., Pour, L., Penka, M., Rysava, R., Nemec, P., Brozova, L., Vychytilova, P., Jurczyszyn, Artur, Grosicki, S., Barchnicka, A., Hajduch, M., Simicek, M., Hajek, R.   +17 more
openaire   +4 more sources

Light-Chain (AL) Amyloidosis [PDF]

Clinical Journal of the American Society of Nephrology, 2006
Light-chain (AL) amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. The disease often is difficult to recognize because of its broad range of manifestations and what often are vague symptoms.
openaire   +2 more sources